Table 3.

Medication-related factors of MAVs as identified via univariate linear regression analyses

Variable	Univariate
	β	95% CI	P value
Dosing period (in 24-week increments)	0.015	− 0.004, 0.033	0.13
Number of doses/day	− 0.018	− 0.036, 0.0002	0.05
OHAs administered before meals	− 0.012	− 0.050, 0.026	0.54
Administration of OHAs
At breakfast	− 0.010	− 0.075, 0.054	0.75
At lunch	− 0.030	− 0.065, 0.004	0.08
At dinner	− 0.024	− 0.055, 0.007	0.12
Types of OHAs
DPP4 inhibitors	0.021	− 0.009, 0.052	0.17
Metformin	− 0.013	− 0.048, 0.021	0.44
Sulfonylureas	− 0.015	− 0.059, 0.029	0.51
α-Glycosidase inhibitors	− 0.050	− 0.103, 0.003	0.06
SGLT2 inhibitors	0.020	− 0.045, 0.084	0.55
Glinides	0.033	− 0.049, 0.115	0.42

Measurements were carried out using univariate liner regression analysis

β standard regression coefficient, CI confidence interval, DPP4 dipeptidyl peptidase 4, MAVs medication adherence values, OHAs oral hypoglycemic agents, SGLT2 sodium glucose cotransporter 2